The Live Virtual Experience will include top experts sharing highlights from over 25 on-demand presentations*, available 9 September 2021. The on-demand presentations will be available through the virtual platform. These interactive panel discussions will also feature debates and Q&A from the live audience.
9:00 AM (EDT) 15:00 (GMT +2) (CEST) |
5 mins |
Opening Remarks |
Tadeusz Robak, MD, PhD |
Theme 1: Pathogenesis of CLL | |||
9:05 AM (EDT) 15:05 (GMT +2) (CEST) |
5 mins | Session 1: Molecular Pathogenesis of CLL – Genomics and Proteomics ![]() |
Co-Chairs: Catherine J. Wu, MD & Clare Sun, MD |
Genomic Analysis of CLL |
Anna Schuh, MD, PhD | ||
Novel Insights From |
Michael Gillette, MD, PhD | ||
9:10 AM (EDT) 15:10 (GMT +2) (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Genomic Analysis of CLL & *Novel Insights From Proteogenomic Analysis ![]() |
Catherine J. Wu, MD; Clare Sun, MD; Anna Schuh, MD, PhD; Michael Gillette, MD, PhD |
9:40 AM (EDT) 15:40 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
9:50 AM (EDT) 15:50 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
10:00 AM (EDT) 16:00 (GMT +2) (CEST) |
5 mins | Visit Exhibit Hall & Break | |
10:05 AM (EDT) 16:05 (GMT +2) (CEST) |
5 mins | Session 2: Molecular Pathogenesis of CLL – Microenvironment & Signaling![]() |
Co-Chairs: Nicholas Chiorazzi, MD & Sarka Pospisilova, PhD |
Trafficking of CLL Cells To and From the Microenvironmental Niche
|
Andrea Pepper, PhD | ||
Effects of Distinct Receptor-Ligand Systems (BCR, TLR, Chemokine Receptors) in the Survival and Growth of CLL Cells On-Demand Presentation ![]() |
Dimitar Efremov, MD, PhD | ||
Crosstalk of Microenvironmental Elements in the Tissue Microenvironment On-Demand Presentation ![]() |
Alan Ramsay, PhD | ||
10:10 AM (EDT) 16:10 (GMT +2) (CEST) |
36 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Trafficking of CLL Cells To and From the Microenvironmental Niche *Effects of Distinct Receptor-Ligand Systems (BCR, TLR, Chemokine Receptors) in the Survival and Growth of CLL Cells *Crosstalk of Microenvironment Elements in the Tissue Microenvironment ![]() |
Nicholas Chiorazzi, MD; Sarka Pospisilova, PhD; Andrea Pepper, PhD; Dimitar Efremov, MD, PhD; Alan Ramsay, PhD |
10:46 AM (EDT) 16:46 (GMT +2) (CEST) |
7 mins | Live Oral Abstract![]() |
|
10:53 AM (EDT) 16:53 (GMT +2) (CEST) |
7 mins | Live Oral Abstract![]() |
|
11:00 AM (EDT) 17:00 (GMT +2) (CEST) |
5 mins | Visit Exhibit Hall & Break | |
11:05 AM (EDT) 17:05 (GMT +2) (CEST) |
5 mins |
Session 3: Clonal Dynamics, Competition, |
Co-Chairs: Gianluca Gaidano, MD, PhD & Adalgisa Condoluci, MD |
Mechanisms of Epigenetic Dynamics/Evolution On-Demand Presentation ![]() |
Davide Rossi, MD, PhD | ||
Perspectives of Clonal Evolution at the Single-Cell Level On-Demand Presentation ![]() |
Catherine J. Wu, MD | ||
11:10 AM (EDT) 17:10 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
11:20 AM (EDT) 17:20 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
11:30 AM (EDT) 17:30 (GMT +2) (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Mechanisms of Epigenetic Dynamics/Evolution *Perspectives of Clonal Evolution at the Single-Cell Level ![]() |
Gianluca Gaidano, MD, PhD; Adalgisa Condoluci, MD; Davide Rossi, MD, PhD; Catherine J. Wu, MD |
12:00 PM (EDT) 18:00 (GMT +2) (CEST) |
End of Day 1 | ||
12:00 PM (EDT) 18:00 (GMT +2) (CEST) |
60 mins | Poster Session | |
1:00 PM (EDT) 19:00 (GMT +2) (CEST) |
Poster Session Concludes |
Theme 2: Approach Considerations and Treatment Options in CLL | |||
9:00 AM (EDT) 15:00 (GMT +2) (CEST) |
5 mins | Opening Remarks & Recap of Previous Day![]() |
Kostas Stamatopoulos, MD, PhD |
9:05 AM (EDT) 15:05 (GMT +2) (CEST) |
5 mins | Session 4: Prognostication and Prediction in the Era of Novel Drugs ![]() |
Chair: Peter Hillmen, MB ChB, PhD |
The Use of Conventional Prognostic Markers with Targeted Therapy On-Demand Presentation ![]() |
Eugen Tausch, MD | ||
Genomic Profiling and Treatment Decisions in the Non-Chemotherapy Era On-Demand Presentation ![]() |
Romain Guièze, MD | ||
9:10 AM (EDT) 15:10 (GMT +2) (CEST) |
45 mins | Panel Discussion featuring highlights from the following on-demand presentations: *The Use of Conventional Prognostic Markers with Targeted Therapy *Genomic Profiling and Treatment Decisions in the Non-Chemotherapy Era ![]() |
Peter Hillmen, MB ChB, PhD; Eugen Tausch, MD; Romain Guièze, MD |
9:55 AM (EDT) 15:55 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
10:05 AM (EDT) 16:05 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
10:15AM (EDT) 16:15 (GMT +2) (CEST) |
5 mins | Visit Exhibit Hall & Break | |
10:20 AM (EDT) 16:20 (GMT +2) (CEST) |
5 mins | Session 5: Minimal Residual Disease – Methods and Clinical Application![]() |
Co-Chairs: Thomas Kipps, MD, PhD & Kirsten Fischer, MD |
Minimal Residual Disease On-Demand Presentation ![]() |
William Wierda, MD, PhD | ||
10:25 AM (EDT) 16:25 (GMT +2) (CEST) |
20 mins |
Debate: To MRD or Not to MRD – |
Moderator: Thomas Kipps, MD, PhD Debaters: |
10:45 AM (EDT) 16:45 (GMT +2) (CEST) |
25 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Minimal Residual Disease ![]() |
Thomas Kipps, MD, PhD; Kirsten Fischer, MD; William Wierda, MD, PhD |
11:10 AM (EDT) 17:10 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
11:20 AM (EDT) 17:20 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
11:30 AM (EDT) 17:30 (GMT +2) (CEST) |
5 mins | Visit Exhibit Hall & Break | |
11:35 AM (EDT) 17:35 (GMT +2) (CEST) |
60 mins | Industry Supported Satellite Symposia | |
12:35 PM (EDT) 18:35 (GMT +2) (CEST) |
10 mins | Binet/Rai Medal Presentation![]() |
|
12:45 PM (EDT) 18:45 (GMT +2) (CEST) |
5 mins | Session 6: Front-Line Therapy of CLL![]() |
Co-Chairs: Barbara Eichhorst, MD & Lydia Scarfo, MD |
Relevant Factors for Choice of Frontline Therapy On-Demand Presentation ![]() |
Arnon Kater, MD, PhD | ||
Treatment of Very High Risk CLL (TP53, Complex Karyotype; IGHV Subset 2) On-Demand Presentation ![]() |
Inhye Ahn, MD | ||
Chemotherapy in the Front Line Setting: Is it Still Useful in Combination with Newer Substances? On-Demand Presentation ![]() |
Matthew Davids, MD, MMSc | ||
12:50 PM (EDT) 18:50 (GMT +2) (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Relevant Factors for Choice of Frontline Therapy *Treatment of Very High Risk CLL (TP53, Complex Karyotype; IGHV Subset 2) *Chemotherapy in the Front Line Setting: Is it Still Useful in Combination with Newer Substances? ![]() |
Barbara Eichhorst, MD; Lydia Scarfo, MD; Arnon Kater, MD, PhD; Inhye Ahn, MD; Matthew Davids, MD, MMSc |
1:20 PM (EDT) 19:20 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
1:30 PM (EDT) 19:30 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
1:40 PM (EDT) 19:40 (GMT +2) (CEST) |
End of Day 2 | ||
1:40 PM (EDT) 19:40 (GMT +2) (CEST) |
60 mins | Poster Session | |
2:40 PM (EDT) 20:40 (GMT +2) (CEST) |
Poster Session Concludes |
9:00 AM (EDT) 15:00 (GMT +2) (CEST) |
5 mins | Opening Remarks & Recap of Previous Day |
Jan Burger, MD, PhD |
9:05 AM (EDT) 15:05 (GMT +2) (CEST) |
5 mins | Session 7: Treatment of Relapsed/Refractory CLL![]() |
Co-Chairs: John Seymour, MD & Meghan Thompson, MD |
Resistance to Venetoclax: Mechanisms, Risk Factors and Preventative Strategies On-Demand Presentation ![]() |
Andrew Roberts, MBBS, PhD | ||
A Clinical Perspective on Resistance to Covalent BTKi On-Demand Presentation ![]() |
Jennifer Woyach, MD | ||
Using Genomics and Biologic Profiling to Select the Preferred Targeted Agent for Each Patient On-Demand Presentation ![]() |
Richard Rosenquist, MD, PhD | ||
9:10 AM (EDT) 15:10 (GMT +2) (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Resistance to Venetoclax: Mechanisms, Risk Factors, and Preventative Strategies *A Clinical Perspective on Resistance to Covalent BTKi *Using Genomics and Biologic Profiling to Select the Preferred Targeted Agent for Each Patient ![]() |
John Seymour, MD; Meghan Thompson, MD; Andrew Roberts, MBBS, PhD; Jennifer Woyach, MD; Richard Rosenquist, MD, PhD |
9:40 AM (EDT) 15:40 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
9:50 AM (EDT) 15:50 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
10:00AM (EDT) 16:00 (GMT +2) (CEST) |
5 mins | Visit Exhibit Hall & Break | |
Theme 3: Rationally Designed Therapy on the Horizon in CLL |
|||
10:05 AM (EDT) 16:05 (GMT +2) (CEST) |
5 mins | Session 8: New Agents in CLL Clinical Trials![]() |
Co-Chairs: Jennifer Woyach, MD & Lindsey Roeker, MD |
Refining our Standard Approaches On-Demand Presentation ![]() |
Paolo Ghia, MD, PhD | ||
Reversible BTK Inhibitors On-Demand Presentation ![]() |
Jennifer Brown, MD, PhD | ||
Preclinical Methods for Drug Discovery On-Demand Presentation ![]() |
Rosa Lapalombella, PhD | ||
10:10 AM (EDT) 16:10 (GMT +2) (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Refining our Standard Approaches *Reversible BTK Inhibitors *Preclinical Methods for Drug Discovery ![]() |
Jennifer Woyach, MD; Lindsey Roeker, MD; Paolo Ghia, MD, PhD; Jennifer Brown, MD, PhD; Rosa Lapalombella, PhD |
10:40 AM (EDT) 16:40 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
10:50 AM (EDT) 16:50 (GMT +2) (CEST) |
10 mins | Live Oral Abstract![]() |
|
11:00 AM (EDT) 17:00 (GMT +2) (CEST) |
60 mins | Industry Supported Satellite Symposia![]() |
|
12:00 AM (EDT) 18:00 (GMT +2) (CEST) |
5 mins | Visit Exhibit Hall & Break | |
12:05 PM (EDT) 18:05 (GMT +2) (CEST) |
5 mins | Session 9: Immunotherapy of CLL![]() |
Co-Chairs: John Gribben, MD, DSc & David Maloney, MD, PhD |
12:10 PM (EDT) 18:10 (GMT +2) (CEST) |
30 mins | Debate – CAR T-cell Therapy vs Allo-SCT![]() |
Moderators: John Gribben, MD, DSc; Debaters: |
T Cells in CLL Biology and Treatment: Friends or Foe? |
Jan Burger, MD, PhD | ||
Bispecific Monoclonal Antibodies On-Demand Presentation ![]() |
Adrian Wiestner, MD, PhD | ||
12:40 PM (EDT) 18:40 (GMT +2) (CEST) |
12 mins | Live Oral Abstract![]() |
|
12:52 PM (EDT) 18:52 (GMT +2) (CEST) |
12 mins | Live Oral Abstract![]() |
|
1:05 PM (EDT) 19:05 (GMT +2) (CEST) |
25 mins | Panel Discussion featuring the following on-demand presentations: *Bispecific Monoclonal Antibodies *T Cells in CLL Biology and Treatment: Friends or Foe? |
John Gribben, MD, DSc David Maloney, MD, PhD Jan Burger, MD, PhD Adrian Wiestner, MD, PhD Jordan Gauthier MD, MSc Peter Dreger, MD |
1:30 PM (EDT) 19:30 (GMT +2) (CEST) |
End of Day 3 | ||
1:30 PM (EDT) 19:30 (GMT +2) (CEST) |
60 mins | Poster Session | |
2:30 PM (EDT) 20:30 (GMT +2) (CEST) |
Poster Session Concludes | ||
2:45 PM (EDT) 20:45 (GMT +2) (CEST) |
60 mins | Industry Supported Satellite Symposium |
9:00 AM (EDT) 15:00 (GMT +2) (CEST) |
5 mins | Opening Remarks & Recap of Previous Day![]() |
Tamar Tadmor, MD |
9:05 AM (EDT) 15:05 (GMT +2) (CEST) |
5 mins | Session 10: Supportive Care and Consequences of Immune Dysregulation in CLL ![]() |
Co-Chairs: Jennifer Brown, MD, PhD & Jackie Barrientos, MD |
Infection Risk in CLL On-Demand Presentation ![]() |
Carsten Niemann, MD, PhD |
||
Infection Risk with Novel Agents On-Demand Presentation ![]() |
Florence Cymbalista, MD, PhD |
||
COVID-19 and CLL On-Demand Presentation ![]() |
Lydia Scarfò, MD |
||
Management of Autoimmune Cytopenias in the Era of Targeted Agents On-Demand Presentation ![]() |
Kerry Rogers, MD |
||
Management of Cardiac Complications of BTK Inhibitors On-Demand Presentation ![]() |
Javid Moslehi, MD |
||
9:10 AM (EDT) 15:05 (GMT +2) (CEST) |
5 mins | Live Oral Abstract![]() |
|
9:15 AM (EDT) 15:15 (GMT +2) (CEST) |
5 mins | Live Oral Abstract![]() |
|
9:20 AM (EDT) 15:20 (GMT +2) (CEST) |
35 mins | Panel Discussion featuring the following on-demand presentations: *Infection Risk in CLL *Infection Risk with Novel Agents *COVID-19 and CLL *Management of Autoimmune Cytopenias in the Era of Targeted Agents *Management of Cardiac Complications of BTK Inhibitors ![]() |
Jennifer Brown, MD, PhD; Jackie Barrientos, MD; Carsten Niemann, MD, PhD; Florence Cymbalista, MD, PhD; Kerry Rogers, MD; Lydia Scarfò, MD; Javid Moslehi, MD |
9:55 AM (EDT) 15:55 (GMT +2) (CEST) |
60 mins | Industry Supported Satellite Symposia | |
10:55 AM (EDT) 16:55 (GMT +2) (CEST) |
5 mins | Visit Exhibit Hall & Break | |
Theme 4: From Global Perspectives to Patient Experiences – How iwCLL Is Leading the Way | |||
11:00 AM (EDT) 17:00 (GMT +2) (CEST) |
5 mins | Session 11: Real-World Data and Patient Experiences![]() |
Co-chairs: Peter Hillmen, MB ChB, PhD; John Seymour, MD |
11:05 AM (EDT) 17:10 (GMT +2) (CEST) |
10 mins | The iwCLL Global Partnerships Sub-Committee Update![]() |
Anna Schuh, MD, PhD |
11:15 AM (EDT) 17:15 (GMT +2) (CEST) |
7 mins | ERIC Updates![]() |
Paolo Ghia, MD, PhD |
11:22 AM (EDT) 17:22 (GMT +2) (CEST) |
7 mins | Update on Geographic Diversity and Management of CLL in China ![]() |
Shenmiao Yang, MD |
11:29 AM (EDT) 17:29 (GMT +2) (CEST) |
7 mins | Update on Geographic Diversity and Management of CLL in South America ![]() |
Carlos Sergio Chiattone, MD, MSc, PhD |
11:36 AM (EDT) 17:36 (GMT +2) (CEST) |
7 mins | Update on Geographic Diversity and Management of CLL in Africa ![]() |
Clara Chamba, MD |
11:43 AM (EDT) 17:43 (GMT +2) (CEST) |
5 mins | Live Oral Abstract![]() |
|
11:48 AM (EDT) 17:48 (GMT +2) (CEST) |
5 mins | Live Oral Abstract![]() |
|
11:53 AM (EDT) 17:53 (GMT +2) (CEST) |
15 mins | Real-World Data Roundtable Discussion![]() |
Peter Hillmen, MB ChB, PhD Anna Schuh, MD Paolo Ghia, MD, PhD Shenmiao Yang, MD Carlos Sergio Chiattone, MD, MSc, PhD Clara Chamba, MD |
12:08 PM (EDT) 18:08 (GMT +2) (CEST) |
7 mins | Visit Exhibit Hall & Break | |
12:15 PM (EDT) 18:15 (GMT +2) (CEST) |
Session 11: Real-World Data and Patient Experiences (Part 2) |
||
12:15 PM (EDT) 18:15 (GMT +2) (CEST) |
45 mins | Live Panel Discussion: Spotlight on the CLL Patient Experience: Perspectives Learned From Three Datasets & Patient Experience/Perspective/Solutions ![]() |
John Seymour, MD; Deborah Sims; Dr. Brian Koffman, CMO and EVP, CLL Society; Lorna Warwick, CEO, Lymphoma Coalition; Zack Pemberton-Whiteley, CEO, Leukaemia Care |
1:00 PM (EDT) 19:00 (GMT +2) (CEST) |
5 mins | Session 12: Looking to the Future of CLL and iwCLL | Michael Hallek, MD, PhD; Peter Hillmen, MB ChB, PhD |
1:05 PM (EDT) 19:05 (GMT +2) (CEST) |
30 mins | Keynote: Advances in CLL: Is It Time to Talk Cure?![]() |
Michael Hallek, MD, PhD |
1:35 PM (EDT) 19:35 (GMT +2) (CEST) |
15 mins | iwCLL Updates and iwCLL 2023![]() |
Peter Hillmen, MB ChB, PhD; Jennifer Brown, MD, PhD |
1:50 PM (EDT) 19:50 (GMT +2) (CEST) |
5 mins | Closing Comments![]() |
Michael Hallek, MD, PhD |
1:55 PM (EDT) 19:55 (GMT +2) (CEST) |
Close of Workshop |